Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Kala Pharmaceuticals (KALA) Reports In-Line Q2 EPS
August 6, 2020 8:55 AM EDTKala Pharmaceuticals (NASDAQ: KALA) reported Q2 EPS of ($0.41), in-line with the analyst estimate of ($0.41).
We are very pleased with our progress in the second quarter, said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. In May, the FDA accepted our NDA... More
